NASDAQ:PSTV Plus Therapeutics (PSTV) Stock Price, News & Analysis $1.60 -0.18 (-10.11%) As of 10/2/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Plus Therapeutics Stock (NASDAQ:PSTV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Plus Therapeutics alerts:Sign Up Key Stats Today's Range$1.54▼$1.8650-Day Range$1.78▼$3.9652-Week Range$2.90▼$23.42Volume234,618 shsAverage Volume116,506 shsMarket Capitalization$11.01 millionP/E RatioN/ADividend YieldN/APrice Target$51.75Consensus RatingHold Company Overview Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive agents directly to tumors while limiting exposure to surrounding healthy tissue. Its lead investigational product is rhenium-186 nanoliposome, also known as 186RNL or RNL. The treatment uses nanoliposomes to encapsulate the radioisotope rhenium-186 and is being evaluated for cancers affecting the central nervous system, including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics is also studying potential applications in other solid tumors. Plus Therapeutics is headquartered in Austin, Texas, and conducts its development activities through collaborations with clinical and research institutions. The company was formerly known as Cytori Therapeutics before adopting the Plus Therapeutics name. Marc H. Hedrick serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Plus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScorePSTV MarketRank™: Plus Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 764th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingPlus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialPlus Therapeutics has a consensus price target of $51.75, representing about 3,134.4% upside from its current price of $1.60.Amount of Analyst CoveragePlus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Plus Therapeutics are expected to grow in the coming year, from ($3.76) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Plus Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPlus Therapeutics has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PSTV. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Plus Therapeutics this week, compared to 3 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of Plus Therapeutics is held by insiders.Percentage Held by Institutions3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Receive PSTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PSTV Stock News HeadlinesPlus Therapeutics’ CNSide Begins Billing as Test Volumes SurgeOctober 1 at 5:02 AM | americanbankingnews.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Hold" by BrokeragesSeptember 22, 2026 | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based RepaymentSeptember 10, 2026 | globenewswire.comCerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business LinesAugust 20, 2026 | globenewswire.comCerenome Reports Second Quarter 2026 Financial Results and Business UpdateAugust 14, 2026 | globenewswire.comCerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered LivesAugust 13, 2026 | globenewswire.comPlus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology CompanyJuly 31, 2026 | finanznachrichten.deSee More Headlines PSTV Stock Analysis - Frequently Asked Questions How have PSTV shares performed this year? Plus Therapeutics' stock was trading at $12.8075 at the start of the year. Since then, PSTV shares have decreased by 87.5% and is now trading at $1.60. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:PSTV) announced its earnings results on Thursday, August, 13th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.43. The company earned $0.41 million during the quarter, compared to the consensus estimate of $1.11 million. Plus Therapeutics had a negative trailing twelve-month return on equity of 198.48% and a negative net margin of 230.24%. When did Plus Therapeutics' stock split? Shares of Plus Therapeutics reverse split on Thursday, April 2nd 2026.The 1-25 reverse split was announced on Tuesday, March 31st 2026. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Plus Therapeutics? Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Plus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO) and Adobe (ADBE). Company Calendar Last Earnings8/13/2026Today10/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PSTV Previous SymbolNASDAQ:CYTX CIK1095981 Webwww.plustherapeutics.com Phone737-255-7194Fax858-450-4335Employees20Year Founded1996Price Target and Rating Average Price Target for Plus Therapeutics$51.75 High Price Target$75.00 Low Price Target$25.00 Potential Upside/Downside+3,134.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.39 million Net Margins-230.24% Pretax Margin-230.24% Return on Equity-198.48% Return on Assets-73.13% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio2.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book2.22Miscellaneous Outstanding Shares6,884,000Free Float6,712,000Market Cap$11.01 million OptionableNot Optionable Beta1.40 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PSTV) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our Partners100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
